Triggering drug use in patients with psoriasis: an investigative report from Turkey

Basit Öğe Kaydı
dc.authoridHIZ, Meliha Merve/0000-0003-4303-9717
dc.contributor.authorOgretmen, Zerrin
dc.contributor.authorAskin, Ulku
dc.contributor.authorHiz, Meliha Merve
dc.contributor.authorCevizci, Sibel
dc.date.accessioned2025-01-27T20:22:50Z
dc.date.available2025-01-27T20:22:50Z
dc.date.issued2014
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractIntroduction: The patients clinically diagnosed with psoriasis were investigated for drug use that may trigger psoriasis. Aim: To minimize the triggering drug use and help the medical treatment of psoriasis patients. Material and methods: The study involved 289 psoriatic patients who attended our clinic in 2010-2012 and were asked to bring their drug lists of the last year, which they obtained from the pharmacy's record system. They were advised not to use the drugs that may trigger psoriasis. Data analyses were performed using SPSS program version 19.0. Results: A total of 289 patients were included in the study. Two hundred and twenty-one patients were using non-steroidal anti-inflammatory drugs; 133 patients were using anti-reflux drugs; 35 patients were using antidiabetic drugs; 31 patients were using calcium-channel blockers and 24 patients were using beta-blockers. In our study group, there was no significantly difference between median PASI scores of the patients using a triggering drug and those of who are not using a triggering drug. However, there was a positive low correlation between PASI rates and numbers of drugs used (r = 0.180, p = 0.013). Conclusions: Many other factors may trigger psoriasis, therefore the effect of stopping or minimizing the drug use on disease remission is not known. Because of the high triggering drug use rate, it is important to enlighten psoriasis patients about triggering drugs.
dc.identifier.doi10.5114/pdia.2014.44019
dc.identifier.endpage298
dc.identifier.issn1642-395X
dc.identifier.issue5
dc.identifier.pmid25395925
dc.identifier.scopus2-s2.0-84908510988
dc.identifier.scopusqualityQ2
dc.identifier.startpage294
dc.identifier.urihttps://doi.org/10.5114/pdia.2014.44019
dc.identifier.urihttps://hdl.handle.net/20.500.12428/22045
dc.identifier.volume31
dc.identifier.wosWOS:000344582300003
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTermedia Publishing House Ltd
dc.relation.ispartofPostepy Dermatologii I Alergologii
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectpsoriasis
dc.subjecttriggering drugs
dc.subjectbeta-blockers
dc.subjectnon-steroidal anti-inflammatory drugs
dc.titleTriggering drug use in patients with psoriasis: an investigative report from Turkey
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu